Medical Devices New Zealand

New Zealand Molecular Diagnostics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

New Zealand Molecular Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Technology, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

New Zealand · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $301.9 Mn Placeholder estimate
Estimate 2025 $332.4 Mn 1.1% of the global market
Projected 2034 $790.2 Mn 137.7% Adds $457.8 Mn over 9 forecast years
CAGR 2025–2034 10.1% Faster than 60% of 167 Medical Devices markets here
Key players 6 +1
  • New Zealand is 1.1% of the global market.
  • In APAC, the largest is China at $2.70 Bn.
  • Fastest growing: India at 12.7% a year.
  • New Zealand ranks 6th of 14 by size in APAC.

Market size projection

New Zealand

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$457.8 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Molecular Diagnostics Market market size by year, New Zealand
YearMarket sizeChange that yearSince 2025
2024 (estimate) $301.9 Mn — —
2025 (base) $332.4 Mn +$30.5 Mn —
2026 (forecast) $366.0 Mn +$33.6 Mn +10.1%
2027 (forecast) $402.9 Mn +$37.0 Mn +21.2%
2028 (forecast) $443.6 Mn +$40.7 Mn +33.5%
2029 (forecast) $488.4 Mn +$44.8 Mn +46.9%
2030 (forecast) $537.7 Mn +$49.3 Mn +61.8%
2031 (forecast) $592.1 Mn +$54.3 Mn +78.1%
2032 (forecast) $651.9 Mn +$59.8 Mn +96.1%
2033 (forecast) $717.7 Mn +$65.8 Mn +115.9%
2034 (forecast) $790.2 Mn +$72.5 Mn +137.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

New Zealand Molecular Diagnostics Market Analysis at a glance
Market size, 2025$332.4 Mn placeholder estimate
Forecast, 2034$790.2 Mn placeholder estimate
Growth (CAGR), 2025–203410.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTechnology, application and end user (see all)
Key playersRoche, Abbott Laboratories, Thermo Fisher Scientific Inc., Qiagen N.V., Hologic, Inc. and 1 more (see all)
Regulator in New ZealandMedsafe (WAND)Source: Medsafe. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The New Zealand Molecular Diagnostics Market Analysis Executive Summary

Molecular diagnostics tests read DNA, RNA and proteins to find infections, cancer and inherited disease.

Key segments of the molecular diagnostics market include technology (PCR, Sequencing and Isothermal Amplification) and application (Infectious Disease, Oncology and Genetic Disease).

Bar chart: New Zealand Molecular Diagnostics market size, 2024–2034, placeholder estimates. $301.9 Mn in 2024, $332.4 Mn in 2025 and $790.2 Mn in 2034, 10.1% CAGR.
New Zealand Molecular Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

New Zealand Molecular Diagnostics Market Dynamics

Market Growth Drivers

Falling costs of testing, more demand for precision medicine and steady research spending by drug makers and labs are driving the molecular diagnostics market.

Opportunity

Automation, smaller and cheaper instruments and growth in cancer and genetic testing give the molecular diagnostics market room to grow.

Market Restraints

Costly instruments, a shortage of skilled lab staff and uneven payment for new tests hold back the molecular diagnostics market.

Competitive Landscape for Molecular Diagnostics Market in New Zealand

The molecular diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Molecular Diagnostics Market in New Zealand

Molecular Diagnostics in New Zealand: rules and payment

Medical devices do not need approval before sale, but suppliers must notify them to the WAND database run by Medsafe.⁠[1] Pharmac decides which medicines and medical devices the public health system pays for.⁠[2]

[1] Medsafe. Checked 14 Nov 2026.

[2] Pharmac. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how molecular diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in New Zealand.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Molecular Diagnostics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Molecular Diagnostics in context

New Zealand compared

  • Health spending per person: 5,022 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 17 countries we cover in APAC.[1]
  • Doctors: 3.61 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 17.6% of people (2025). World: 10.4% of people (2025). 5th highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 21 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Molecular Diagnostics market in New Zealand?
Placeholder estimate: about $332.4 Mn in 2025, rising to about $790.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Molecular Diagnostics market in New Zealand growing?
Placeholder estimate: about 10.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Molecular Diagnostics market report cover?
The report splits the market by technology (PCR, Sequencing, Isothermal Amplification, Microarrays and more), application (Infectious Disease, Oncology, Genetic Disease, Blood Screening) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Molecular Diagnostics market?
Key players include Roche, Abbott Laboratories, Thermo Fisher Scientific Inc., Qiagen N.V., Hologic, Inc. and Danaher Corporation.
What is driving the Molecular Diagnostics market?
Falling costs of testing, more demand for precision medicine and steady research spending by drug makers and labs are driving the molecular diagnostics market.
Who regulates Molecular Diagnostics in New Zealand?
Medical devices do not need approval before sale, but suppliers must notify them to the WAND database run by Medsafe. Source: Medsafe. Checked 14 Nov 2026.
How is healthcare paid for in New Zealand?
Pharmac decides which medicines and medical devices the public health system pays for. Source: Pharmac. Checked 14 Nov 2026.
Back to Catalogue

Related Medical Devices reports in New Zealand

See all

Related on diagnostics and lab testing and genomics

See the topic